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Abstract
Background: The Transforming Growth Factor-β (TGF-β) regulates myriad cellular events by
signaling through members of the Smad family signal transducers. As a key signal transducer of TGF-
β, Smad3 exhibits the property of receptor-activated transcriptional modulator and also the novel
ability of regulating the proteasomal degradation of two Smad3 interacting proteins, SnoN and
HEF1. It has been shown that Smad3 recruits two types of Ub E3 ligases, Smurf2 and the Anaphase
Promoting Complex (APC), to mediate SnoN ubiquitination, thereby enhancing SnoN degradation.
The molecular mechanisms underlying Smad3-regulated HEF1 degradation are not well
understood. Furthermore, it is not clear how Smad3 recruits the APC complex.
Results: We detected physical interaction between Smad3 and an APC component APC10, as well
as the interaction between HEF1 and CDH1, which is the substrate-interacting component within
APC. Detailed domain mapping studies revealed distinct subdomains within the MH2 domain of
Smad3 for binding to APC10 and HEF1 and suggests the formation of a complex of these four
proteins (Smad3, HEF1, APC10 and CDH1). In addition, the protein levels of HEF1 are subjected
to the regulation of overexpressed APC10 and CDH1.
Conclusions: Our data suggests that Smad3 may recruit the APC complex via a direct interaction
with the APC subunit APC10 to regulate the ubiquitination and degradation of its interactor HEF1,
which is recognized as an ubiquitination substrate by the CDH1 subunit of the APC complex.
Background
The Transforming Growth Factor β (TGF-β) superfamily
consists of a large group of structurally related polypep-
tides including various forms of TGF-β, bone morpho-
genic proteins (BMPs), activins, growth and
differentiation factors (GDFs) and the Anti-Mullerian
Hormone (AMH, or MIS) [1,2]. Members of the TGF-β
subfamily are molecular organizers for tissue and organ
morphogenesis during embryonic development and play
key roles in maintaining the homeostasis of various devel-
oped systems [3,4]. At the cellular level, diverse processes
including cell proliferation, differentiation, adhesion and
apoptosis are subjected to TGF-β regulation [5]. The intra-
cellular signaling events are initiated upon TGF-β binding
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to a pair of Ser/Thr kinase receptors known as the Type I
receptor (TβR1) and the Type II receptor (TβRII), which
are structurally similar but functionally distinct [6,7].
Upon binding to TGF-β, the Type II receptor recruits and
activates the type I receptor by releasing the immunophi-
lin FKBP12 from the type I receptor and also by mediating
the trans-phosphorylation of the type I receptor at the GS
domain, a highly conserved thirty-amino acid region con-
taining a SGSGSG sequence [8-10]. The GS domain phos-
phorylation allows the Type I receptor to recruit and
phosphorylate the cytoplasmic proteins belonging to the
family of the Smad proteins [11,12].
The Smad proteins are the vertebrate homologues of the
mothers against Dpp in Drosophila and the C. elegans Sma
proteins [5,13-16]. Based upon their functional proper-
ties, Smad proteins are divided into three classes: 1) the
receptor-regulated Smads, or R-Smads, which are phos-
phorylated respectively by TGF-β/activin receptors for
Smad2 and Smad3 and by BMP receptors for Smad1,
Smad5 and Smad8; 2) the co-mediator Smad (Co-
Smads), namely Smad4 in mammals and Smad10 in
Xenopus and 3) the inhibitor Smads (I-Smads) Smad6 and
Smad7 which prevent the phosphorylation of the R-
Smads and sometimes the formation of a complex
between R-Smads and Co-Smads. Smad proteins have two
conserved globular domains, namely N or Mad homology
1 (MH1) domain and C or MH2 domain, separated by a
linker region of variable length and which can associate
with one another in the inactive state. Upon phosphoryla-
tion by TGF-β type I receptor, Smad2 and Smad3 form a
complex with Smad4 and translocate into the nucleus
where they function as transcription factors. However, a
novel activity of Smad3 in regulating the proteasomal
degradation of the nuclear proto-oncoprotein SnoN and
of the human enhancer of filamentation 1 (HEF1) has
recently been reported. The data also suggest possible
roles of proteasomal degradation of HEF1 and SnoN in a
negative feedback mechanism of the TGF-β signaling
pathway [17-19].
HEF1 was first isolated in a screen for human proteins
capable of inducing pseudohyphal growth in Saccharomy-
ces cerevisiae [20]. HEF1, also known as CasL, is a cytoplas-
mic docking protein belonging to the Cas family and
structurally related to p130Cas and Efs. HEF1 is predomi-
nantly expressed in epithelial cells and lymphocytes. It
contains multiple protein-protein interaction domains
including a N-terminal SH3 domain that binds polypro-
line-containing protein, a domain containing multiple
SH2 binding sites, a Serine-rich domain and a conserved
C-terminal domain containing a helix-loop-helix (HLH)
motif [21]. HEF1 is processed in a complex manner since
at least four protein species (p55HEF1, p65HEF1, p105HEF1
and p115HEF1) can result from a single cDNA expressed in
vivo  in a cell cycle-dependent manner. p105HEF1  and
p115HEF1 represent different phosphorylation states of the
full length HEF1 and are more predominantly cytoplas-
mic whereas p55HEF1 arises through cleavage of the full
length HEF1 during mitosis [17,22]. HEF1 has been
implicated in many pathways including the signaling
pathway of integrin, T-cell antigen receptor (TCR), B-cell
receptor (BCR), the G protein coupled calcitonin receptor,
cell adhesion as well as in the progression of the cell cycle
through mitosis [22-26]. HEF1 has also recently been
described as an apoptotic mediator at focal adhesion sites
[21]. However the exact nature of the signaling events
associated with HEF1 is still unknown.
In TGF-β induced signaling events mediated by Smad3, it
has been shown that Smad3 interacts with both the N-ter-
minus and the C-terminus domains of HEF1 via its MH1
and MH2 domains respectively [17]. Such an interaction
appears to trigger rapid proteasomal degradation of HEF1.
A similar example is the ability of Smad3 to bind to the
nuclear transcriptional co-repressor SnoN, which is also
degraded by the proteasome pathway upon binding to
Smad3 [18,19].
The 26S proteasome is a large proteolytic complex present
both in the nucleus and the cytosol of eukaryotic cells.
Most known proteasome substrate proteins require poly-
ubiquitination to be targeted to the proteasome for degra-
dation. Ubiquitination occurs through the sequential
action of three enzymes [27]. First, the activating enzyme
E1 activates ubiquitin. Ubiquitin is then transferred to an
E2 ubiquitin conjugating enzyme or Ubc. Finally, an
ubiquitin protein ligase or E3 enzyme covalently attaches
the ubiquitin to lysine residues present on the substrate
protein. There are several classes of E3 ligase which appear
to be responsible for substrate selectivity by binding
directly or indirectly to the protein substrate: 1) N-end
rule E3s; 2) the HECT (Homologous to E6-AP C-termi-
nus) domain family which includes the Smurf family and
3) the RING finger containing E3s. The latest are often
part of a large protein complex such as the SCF (Skp1 cul-
lin F-box protein) or the APC (Anaphase-promoting com-
plex) which both belong to the cullin subfamily [28].
The mechanism of Smad3-binding-dependent proteaso-
mal degradation of HEF1 is unknown. For SnoN, it has
been shown to involve at least two different mechanisms.
First, Smad3 has been shown to recruit the HECT family
E3 ligase Smurf2 to regulate SnoN ubiquitination [18].
Smad3 has also been shown to recruit the APC complex to
regulate SnoN degradation [18,19]. The APC or cyclos-
ome is a cell cycle-regulated complex composed of at least
eleven subunits in mammalian cells, APC11 being the
RING finger containing subunit. It is required for the met-
aphase-anaphase transition and cyclin degradation. TwoBMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/20
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WD-40 proteins, namely CDC20 and CDH1, activate APC
by direct binding during mitosis and G1 phase respec-
tively [29]. CDC20 only interacts with proteins containing
a destruction box or D-box whereas CDH1 can recognize
either the D-box or the KEN-box motifs present both in
cell-cycle specific and non cell-cycle proteins [30]. Most of
the APC subunits are conserved from yeast to humans.
Preliminary data from the yeast two-hybrid system sug-
gests that Smad3 interacts with APC10. APC10/Doc1 is a
one-domain protein that has a conserved core, the Doc
domain, which is homologous to domains found in sev-
eral other putative E3 ligases [31,32]. Doc domain-con-
taining proteins may mediate ubiquitination because they
contain combinations of RING finger, cullin or HECT
domains [31]. Moreover, additional data suggest that
APC10 is essential for APC function in mammals. Indeed,
rearrangements in the APC10 gene locus appear to under-
lie the mitotic arrest phenotype observed in mice
homozygous for the embryonic-lethal developmental
mutation oligosyndactylism [33]. Structural analyses of
APC10 also suggest that APC10 could mediate or modify
the ubiquitination reaction of the APC [32,34].
Here we report the biochemical studies of the interaction
between Smad3 and APC10, between HEF1 and CDH1,
and the evidence for the functional roles of APC10 and
CDH1 in Smad3-regulated HEF1 degradation. These stud-
ies suggest a new mechanism of Smad3 in regulating the
proteasomal degradation of its interacting proteins via
recruiting the cell cycle-linked E3 ligase APC.
Results
Smad3 directly interacts with the Anaphase Promoting 
Complex (APC) subunit APC10
The yeast two-hybrid system developed in Dr. Roger
Brent's laboratory was applied to search for Smad3 inter-
acting proteins, as described previously [17]. Like HEF1,
APC10 was isolated as a strong interactor for Smad3 (data
not shown). APC10 is an integral component of the E3
ligase complex APC and has been suggested to be essential
for APC function in mammals [31,32]. Recent observa-
tions made by others have suggested that the APC com-
plex is able to mediate ubiquitination of SnoN in a
Smad3-dependent fashion [18,19]. However, it is not
clear how Smad3 recruits the APC complex. The ability of
Smad3 to bind APC10 thus suggests a mechanism for
Smad3 to recruit APC complex and point out a possible
role of APC complex in Smad3-regulated HEF1 degrada-
tion. We therefore carried out more detailed biochemical
studies of this pair of interaction in various systems, as
described blow.
First, we tested the ability of APC10 to interact with differ-
ent Smads in a mammalian overexpression system. HA-
tagged Smad proteins (Smad1, Smad2, Smad3, Smad4)
were transiently expressed in 293 cells together with T7-
tagged APC10. The Smads were immunoprecipitated with
anti-HA antibody and the co-precipitated T7-tagged
APC10 was detected by Western blot using anti-T7 anti-
body. T7-APC10 was detected to co-precipitate with
Smad2, Smad3, but not with Smad1 or Smad4 (Fig. 1A).
Thus, the interaction between Smad3 and APC10 is spe-
cific and can occur in mammalian cells.
Next we tested the interaction between APC10 and the
Smad proteins by GST pull-down assay using GST-APC10
expressed and purified from Escherichia coli BL21 and
Flag-tagged Smads expressed in 293 cells. In this assay,
APC10 again binds to the two R-Smads involved in the
TGF-β signaling pathway, Smad2 and Smad3 (Fig. 1B,
lane 2 & 3), but not with the Co-Smad, Smad4 (Fig. 1B,
lane 4).
The interactions were further tested via in vitro binding
assays.  35S-labeled  in vitro translated Smad3 or APC10
proteins were incubated with GST-APC10 or GST-Smad3,
respectively. GST alone was used as a negative control. 35S-
labeled Smad3 was detected to bind GST-APC10 (Fig. 1C,
lane 6); 35S-labled APC10 was detected to bind GST-
Smad3 (Fig. 1C, lane 5). Labeled HEF1 also binds to GST-
Smad3 (Fig. 1C, lane 4). These data suggests that Smad3
can interact with both HEF1 and APC10 in vitro, most
likely via direct interaction.
Smad3 interacts with APC10 via Smad3 MH2 domain and 
requires both N- and C-terminus of APC10
To understand how APC10 interacts with Smad3, we car-
ried out deletion analyses to determine the domains of
interaction on both Smad3 and APC10. First, GST pull
down assays were carried out to test the interaction
between purified GST-APC10 and Flag-tagged Smad3 and
Flag-tagged Smad3 deletion mutants expressed in 293
cells. The tested Smad3 deletion mutants include
Smad3NL, Smad3LC, Smad3 MH1 (Smad3N) and Smad3
MH2 (Smad3C) (Fig. 2A, top panel). Only Smad3LC and
Smad3C exhibited the ability to bind APC10 (Fig. 2A, bot-
tom left panel, lanes 2 & 4). The interaction was also
tested in a mammalian overexpression system 293 cells,
which were co-transfected with T7-APC10 and Flag-
Smad3 deletions. APC10 was immunoprecipitated from
the cell lysates and the co-precipitated Smad3 and its dele-
tion mutants were detected by Western blot with anti-Flag
antibody. Again, only Smad3LC and Smad3C were
detected to co-precipitate T7-APC10 (Fig. 2A, bottom
right panel, lanes 7 & 9). Thus, the MH2 domain of
Smad3 is necessary and sufficient to bind APC10,
although a possible role of the linker region of Smad3 in
assisting the interaction between Smad3 and APC10 is not
ruled out.BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/20
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Further experiments were carried out to determine Smad3
binding domain on APC10. A set of deletion constructs of
APC10 (Fig. 2B, top panel) were made and tested for
expression in 293 cells (Fig. 2B, bottom left panel). All of
the three N-terminal deletion constructs (D2, D3, & D4)
and one C-terminal deletion construct (D7) failed to
express stable proteins (Fig. 2B, bottom left panel, lanes
2–5), while two C-terminal deletion constructs (D8 & D9)
were expressed (Fig. 2B, bottom left panel, lanes 6 & 7).
Thus, the N-terminal 41 amino acids and an internal
domain (a.a.60–a.a 82) play roles in maintaining the sta-
bility of APC10. Both APC10 D2 and APC10 D9, when
expressed in yeast as fusion proteins of B42, failed to bind
the LexA fusion protein of Smad3 in the yeast-two hybrid
Smad3 interacts with APC10 specifically Figure 1
Smad3 interacts with APC10 specifically. (A) Co-immunoprecipitation of Smad3 and APC10 from mammalian overex-
pression system. 293 cells were transiently transfected with T7-APC10 and Smad proteins as indicated. The cell lysates were 
subjected to Western blot analyses directly or immunoprecipitation followed by Western blot as indicated. (B) Smad3 binds to 
APC10 in GST pull down assays. Flag-tagged Smad constructs were transfected into 293 cells and tested against GST-APC10 
purified from E. Coli. Total input Smad protein levels (100 ug) were detected by immunoblotting of the cell lysates with anti-
Flag antibody (top panel). Smad proteins bound to the GST-APC10 beads were eluted and analyzed by immunoblotting with 
anti-Flag antibody (middle panel). As a control, F-Smad proteins were incubated with the GST alone (bottom panel). (*) We 
noted that GST-APC10 was recognized by the anti-Flag antibody on Western blot. (C) Smad3 binds to HEF1 and APC10 in in 
vitro binding assay. In vitro translated 35S-labeled HEF1, 35S Smad3 and 35S APC10 were incubated with GST-Smad3, GST-
APC10 or GST as indicated. The in vitro translated proteins before and after binding were detected by electrophoresis and 
autoradiography.BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/20
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Domain mapping studies of the interaction between Smad3 and APC10 reveal distinct domains involved in binding Figure 2
Domain mapping studies of the interaction between Smad3 and APC10 reveal distinct domains involved in 
binding. (A) The Smad3C (MH2 domain) is necessary and sufficient for binding to APC10. Top panel: a cartoon to illustrate 
the deletion constructs of Smad3. The APC10 binding activities of each truncated Smad3 as detected by assays in the bottom 
panels are summarized at the right side of the panel. Bottom left panel: MH2 domain is necessary and sufficient for Smad3 to 
bind APC10 in GST pull down assay. Flag-tagged full-length or truncated Smad3, as indicated, was transfected into 293 cells and 
tested against GST-APC10 and GST (negative control). Bottom right panel: MH2 domain is necessary and sufficient for Smad3 
to bind APC10 in 293 cells. Different Smad3 truncations tagged with Flag were co-transfected with T7-APC10 into 293 cells. 
The expression of these proteins was detected by Western Blot using anti-Flag and the interaction between APC10 and Smad3 
truncations was detected by immunoprecipitation of T7-APC10 followed by Western blot using anti-Flag. "L.C." represents the 
antibody light chain. (B) The C-terminal domain of APC10 is necessary for binding to Smad3. Top panel: a cartoon that illus-
trates the deletion mutants of APC10. The top three deletion constructs are amino-terminal deletion mutants. The number of 
amino acids deleted in each construct is indicated. For example, the D2 construct lacks the N-terminal 41 amino acids, thus it 
is also labeled as D41N. Bottom left panel: the six deletion constructs of APC10, each tagged with Flag, were transfected into 
293 cells. The expression of these deletion mutants was detected by Western blot using anti-Flag. Stable protein expression 
was detected only in cells transfected with two C-terminal deletion constructs (D8 and D9). Bottom right panel: the C-termi-
nal 66 amino acids of APC10 are required for Smad3 binding. T7-tagged APC10 and Flag-tagged APC10 D9 were transfected 
into 293 cells. Cell lysates were subjected to immunoblotting with anti-T7 (lane 1) and anti-Flag (lane 2) antibody. APC10 and 
APC10 D9 were tested against GST-Smad3 (lanes 3 & 4) and GST alone as a control (lanes 5 & 6).BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/20
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system (data not shown). GST pull-down assay using GST-
Smad3 fusion protein against APC10 D9 confirmed the
defect of this deletion mutant of APC10 in binding to
Smad3 (Fig. 2B, bottom right panel, lane 4). These studies
revealed that the C-terminal 66 amino acids of APC10 is
required for Smad3 interaction while the N-terminal 82
amino acids of APC10 is required for the protein stability.
Different subdomains within the MH2 domain of Smad3 
are involved in binding to APC10 and HEF1
In order to map more precisely the domain on Smad3
necessary for APC10 binding, we tested several Smad3
deletion mutants within the MH2 domain against GST-
APC10. In addition, we also tested the binding property of
a Smad3/Smad1/Smad3 chimera, which contains N-ter-
minus a.a.1–236 and C-terminus a.a. 277–424 but with
part of the MH2 region of Smad3 (a.a. 237–276) replaced
with the co-responding region of Smad1 (a.a. 276–317),
as previously described [18]. Since Smad1 does not inter-
act with APC10 in this assay system, any binding to
APC10 is due to the Smad3C portion of the chimera.
These deletion constructs of Smad3 are illustrated in Fig-
ure 3A. These deletion constructs were transfected into the
293 cells and the expression of each protein was moni-
tored by Western blot analyses with anti-Flag monoclonal
antibody, since they are all tagged with the Flag epitope
(Fig. 3B, top panels). The cell lysates were incubated with
purified GST-APC10 proteins, or control GST proteins
both of which were absorbed onto Glutathione Sepharose
4 Fast Flow beads. The bead bound proteins were eluted
and analyzed by Western blot (Fig. 3B, middle and bot-
tom panels). Smad3 d2, which contains a deletion of the
C-terminal a.a.362–424, still binds strongly with APC10
(Fig. 3B, lane 1). Further deletion of a.a.330–362 (Smad3
d6) led to a significant reduction of interaction (Fig. 3B,
lane 3), and more deletion of a.a. 301–330 (Smad3 d4)
further weakened the interaction (Fig. 3B, lane 2). Densi-
tometry analyses of the protein signals were used to calcu-
late the relative percent of APC10-bound proteins in total
input proteins, by dividing the protein signals in GST-
APC10 panel by those in lysates panel. The derived rela-
tive percentages are indicated at the top right side of Fig.
3B. An abrupt drop of percentage occurs between Smad3
d2 (95%) and Smad3 d6 (34%), with an additional small
reduction between Smad3 d6 (34%) to Smad3 d4 (17%).
These data suggests that the amino acid residues 301 to
362, especially 301 to 330, are important for Smad3/
APC10 binding. The Smad3/Smad1/Smad3 chimera
(20%) exhibited much reduced binding ability compared
with Smad3 d2, suggesting that the region of Smad3
replaced by Smad1, a. a. 237 to 276, is also critical for
APC10 binding. Taken all these data together, we have
mapped residue 237 to 362 within Smad3MH2 to be
involved in APC10 binding.
Since Smad3 MH2 domain has also been shown to bind
HEF1 [17], we decided to compare Smad3 interaction
with both APC10 and HEF1, in order to better understand
the way APC10, Smad3 and HEF1 form a potential ternary
complex. Thus, the same set of cell lysates from 293 cells
transfected with Smad3 deletion constructs were tested
against bead-bound, purified GST-HEF1 and GST, the
later served as a negative control. The bead-bound pro-
teins were eluted and detected by Western blot (Fig. 3C,
middle and bottom panels). The percentage of bound-
protein signals over the lysate protein signals was also
calculated and presented at the top right side of Figure 3C.
The interaction between Smad3d2 with GST-HEF1 (21%)
is not as strong as the interaction between Smad3d2 and
GST-APC10 (95%). Also, there is almost no difference
between Smad3 d2 (21%) and Smad3 d6 (23%) in bind-
ing to GST-HEF1. Thus, the Smad3 MH2 region between
a. a. 330 to 362 is not critical for HEF1 interaction. How-
ever, there is a major difference between Smad3d6 (23%)
and Smad3 d4 (13%) in binding to HEF1, suggesting that
the MH2 region between a.a.301 and 330 is very impor-
tant for Smad3 interaction with HEF1. As for the Smad3/
Smad1/Smad3 chimera, its binding to HEF1 (24%) is as
strong as that for Smad3 d2 (21%), thus suggesting that
the region between a.a. 236 and 276 is not involved in the
interaction between HEF1 and Smad3. By comparing the
different interaction properties of these Smad3MH2
domain mutants exhibited during their binding to APC10
and HEF1, we concluded that different subdomains
within Smad3 MH2 domain are involved in Smad3 bind-
ing to APC10 and HEF1. For binding to APC10, the entire
region between residues 237 to 362 might be involved
(Fig. 3B), while a more localized region between residues
301 to 330 appears to bind HEF1 (Fig. 3C). Combined
with the information reported in our previous studies
[17], we propose a ternary complex formation between
HEF1, Smad3 and APC10, as illustrated in Fig. 3D.
The CDH1 protein in APC complex binds to HEF1
To be ubiquitinated and thus degraded by the proteasome
pathway, APC substrates need first to be recognized by
either CDC20 or CDH1 which targets the ligase to specific
substrates during metaphase-anaphase transition as well
as during late anaphase, respectively [29,35,36]. Recent
studies have demonstrated the direct binding between
APC substrates and CDC20 or CDH1 [37]. CDH1 has also
been shown to bind to the other Smad3 interactor SnoN
in Smad3-regulated SnoN ubiquitination [18,19]. We
thus also examined whether CDH1 interacts with HEF1,
by the direct binding test in vitro. Either GST-HEF1 or GST
alone as a control were incubated with in vitro translated
35S-labeled CDH1. As shown in Figure 4A, in vitro trans-
lated CDH1 binds to GST-HEF1, suggesting a possible
role of CDH1 in targeting HEF1 for APC-mediated ubiq-
uitination of HEF1.BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/20
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Smad3 MH2 domain contains overlapping but distinct binding sites for HEF1 and APC10 Figure 3
Smad3 MH2 domain contains overlapping but distinct binding sites for HEF1 and APC10. (A) A Cartoon to illus-
trate the deletion constructs of Smad3 (Smad3d2, d4 and d6) as well as a hybrid protein S3/S1/S3. (B) GST pull-down assay to 
map APC10 binding site on Smad3C. Flag-tagged Smad3 deletion mutants were transfected into 293 cells and the cell lysates 
were tested against GST-APC10. Cell lysates (top panel) and proteins bound to the beads (middle and bottom panels) were 
analyzed by Western blot with anti-Smad1/2/3 from Santa Cruz. The percentage listed at the right side of the listed constructs 
is derived from dividing the signals (measured by ImageQuant) of bound proteins in the middle panel by the signals of lysate 
proteins in the corresponding lane of the top panel and then times 100 percent. (C) GST pull-down assay to map HEF1 binding 
site on Smad3C. Same as in (B), with GST-APC10 replaced by GST-HEF1. (*) endogenous Smad1 and Smad3 recognized by 
anti-Smad1/2/3 antibody. (D) A cartoon to illustrate the complex of Smad3, HEF1 and APC10 and their potential interaction 
with the APC ligase core complex.BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/20
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CDH1 interacts with HEF1 at the HEF1 C-terminal M2 domain Figure 4
CDH1 interacts with HEF1 at the HEF1 C-terminal M2 domain. (A) In vitro binding test. In vitro translated 35S 
labeled CDH1 was incubated with GST-HEF1 or GST alone as a control in modified lysis buffer. 35S labeled CDH1 was sepa-
rated by electrophoresis and detected by autoradiography. (B) A cartoon that illustrates putative D boxes on HEF1. (C) A car-
toon that illustrates the deletion constructs of HEF1 used in (D). (D) Co-immunoprecipitation of HEF1/HEF1 deletions with 
CDH1 in 293 cells. Full-length HEF1 and T7-tagged HEF1 deletions were co-transfected with myc-tagged CDH1 into 293 cells. 
Myc-CDH1 was immunoprecipitated with anti-myc antiboby and CDH1 bound HEF1 or HEF1 deletions were detected by 
immunoblot with either anti-p130Cas antibody (top panel, lanes 1 & 2) or anti-T7 antibody (top panel, lanes 3–5). The expres-
sion level of CDH1 was detected with anti-myc antibody (second panel). The amount of HEF1 (third panel) or T7-HEF1 dele-
tions (bottom panel) expressed was detected by anti-p130Cas for HEF1 or anti-T7 antibody. (E) A cartoon that illustrate the 
putative complex of HEF1, Smad3, APC and CDH1.BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/20
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CDH1 binds to HEF1 C-terminal M2 domain containing 
two D boxes
Upon examining HEF1 amino acids sequence, we found
five putative D box [RxxLxxxx(N)]. These putative D boxes
are located within the SH3 domain (box 1), the SH2 bind-
ing sites domain (box 2), after the Ser rich domain (box
3) and within the M2 domain of HEF1 (box 4 & 5) (Fig.
4B). D box and KEN motif are the two motifs recognized
by CDH1 on APC substrates [30].
To determine which D box interacts with CDH1, full-
length HEF1 as well as T7-tagged HEF1 deletions, as illus-
trated in a cartoon in Figure 4C, were co-transfected with
myc-tagged CDH1 into 293 cells. Cell lysates were sub-
jected to immunoprecipitation using anti-myc antibody.
Full-length HEF1, HEF1 d113 (114–834) and HEF1 M2
domain (654–834) were found to bind to CDH1 (Fig. 4D,
top panel, lanes 2, 4, & 5). HEF1 1–154 did not show the
ability to bind to CDH1 (Fig. 4D, top panel, lane 3).
Therefore, we predict that CDH1 binds to a D box located
within the M2 (C-terminal) domain that contains two
putative D box, one located between residues 705 and
714 within the HLH motif, the other between amino acids
826 and 834. Since CDH1 is a substrate recognition com-
ponent for APC ligase complex, the ability of CDH1 to
bind to HEF1 suggests that HEF1 is a substrate for the APC
ligase. The detected interactions between Smad3, HEF1,
APC10 and CDH1 is illustrated in a cartoon in Figure 4E.
Smad3 interaction with APC10 is regulated by TGF-β type 
I receptor activation while CDH1 interaction with HEF1 is 
constitutive
To further test the effect of TGF-β receptor activation on
the interaction between Smad3 and APC10 or between
CDH1 and HEF1, these proteins were expressed in 293
cells in the presence or absence of a constitutively acti-
vated TGF-β type I receptor R4T204D (R4TD). As shown
in Figure 5A, APC10 was detected only in the immunopre-
cipitates of Smad3 from cells with the coexpression of
both Smad3 and R4TD (Fig. 5A, lane 6). We noted that
anti-Smad3 precipitates two forms of Smad3 in lane 6
while only one form of Smad3 in lane 5. The higher
molecular weight form is a phosphorylated version of
Smad3, as confirmed by Western blot with anti-phospho-
serine (data not shown). Thus, the data suggests that TGF-
β receptor-induced Smad3 phosphorylation may enhance
its interaction with APC10. This appears to be not the case
for HEF1 interaction with CDH1. As shown in Figure 5B,
the complex formation of CDH1 and HEF1 occurs in the
absence of R4TD and the coexpression of R4TD did not
alter the formation of the complex (Fig. 5B, compare lanes
9 & 10 in top panel). The coexpression of Smad3 with
CDH1 and HEF1 caused significant reduction of HEF1
protein levels, as expected, but also did not alter the com-
plex formation of CDH1 and HEF1 (Fig. 5A, lanes 11 &
12). When HEF1 was coexpressed with CDH1, APC10 and
the MH2 domain of Smad3, which harbors the binding
sites for both HEF1 and CDH1, we detected al four pro-
teins in the immunoprecipitates of HEF1 (Supplementary
Fig. 1). These data further confirms the complex forma-
tion of Smad3, HEF1, CDH1 and APC10 in mammalian
cells and also suggest that TGF-β signaling may regulate
the complex formation via regulating the interaction
between Smad3 and APC10.
APC10 and CDH1 both regulate Smad3-regulated HEF1 
degradation
Since APC10 binds to Smad3, which binds to HEF1 and
induces proteasomal degradation of HEF1 [17], we tested
whether APC10 plays a role in Smad3-regulated proteaso-
mal degradation of HEF1. In 293 cells, HEF1 was co-
expressed with Smad3 in the presence or absence of
APC10. The Smad3-binding defective APC10 D8 was used
as a negative control. As shown in Fig. 6A, the co-expres-
sion of Smad3 alone with HEF1 drastically reduced the
protein level of HEF1, as shown previously (Fig. 6A, lanes
1 & 2). The co-expression of APC10 alone with HEF1 also
caused the reduction of HEF1 level (Fig. 6A, lane 3). Inter-
estingly, the co-expression of APC10 slightly reduced the
ability of Smad3 in causing reduction of HEF1 (Fig. 6A,
lane 4). The effect of overexpressing APC10 alone on
reducing HEF1 protein level appears to be dependent
upon the ability of APC10 to interact with Smad3, since
the Smad3-binding deficient APC10 D8 caused much less
reduction of HEF1 protein level (Fig. 6A, lane 5). It also
failed to interfere with Smad3-induced HEF1 reduction
(Fig. 6A, lane 6). Thus, the overexpression of full length
APC10 or Smad3 alone was sufficient to induce enhanced
HEF1 degradation, while the overexpression of both pro-
teins appears to cause an interference of each protein's
function. Considering the nature of the multimeric com-
plex formation of Smad3, HEF1, APC10 and other APC
components, we would expect this to be the case since
excess of any protein in a multimeric complex would lead
to the un-coupling of the complex formation and there-
fore blocking the normal function of the complex.
To confirm a functional role of CDH1 in proteasomal deg-
radation of HEF1, we also tested the effect of CDH1 on
HEF1 protein level, in the presence or absence of Smad3
and APC10, in 293 cells. Like APC10, overexpression of
CDH1 alone reduced the protein levels of both forms of
HEF1 (Fig. 6B, compare lane 5 with lane 11). The co-
expression of the constitutively activated TGF-β type I
receptor mutant R4T204D (R4TD) caused further reduc-
tion of the p115HEF level in the absence of overexpressed
CDH1 or APC10 (Fig. 6B, compare lanes 11 & 12), but
such a reduction was not very apparent when CDH1,
Smad3, or APC10 was co-expressed either alone or in dif-
ferent combinations (Fig. 6B, compare lanes 1 & 2, 3 & 4,BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/20
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TGF-β type I receptor activation enhances Smad3 interaction with APC10 but does not alter CDH1 interaction with HEF1 Figure 5
TGF-β type I receptor activation enhances Smad3 interaction with APC10 but does not alter CDH1 interac-
tion with HEF1. (A) Smad3 interaction with APC10 is positively regulated by the activation of TGF-β type I receptor. Flag-
Smad3 and T7-APC10 were co-expressed in the presence or absence of a constitutively active TGF-β type I receptor mutant 
R4T204D (R4TD). The interaction between Smad3 and APC10 was detected by immunoprecipitation of Smad3 with an anti-
Smad3 polyclonal antibody followed by Western blot with anti-T7 (Top panel, lanes 4–6). The immunoprecipitated Flag-Smad3 
was detected by anti-Flag antibody (middle panel). The expression of R4TD was detected by anti-TGF-β RI polyclonal antibody 
from Santa Cruz (Bottom panel). R4TD-p represents a potential cleavage product of R4. (B) HEF1 interaction with CDH1 Is 
not regulated by TGF-β type I receptor activation. The 293 cells were transiently transfected with myc-CDH1 and HEF1 in the 
presence or absence of Smad3 and R4TD, as indicated. The interaction between HEF1 and CDH1 was detected by immuno-
precipitation with anti-p130Cas followed by Western blot with anti-myc (Top panel, lanes 7–13). The expression of myc-
CDH1 and Flag-Smad3 was detected by Western blot by anti-myc and anti-Flag (Top panel, lanes 1–6). The expression levels of 
HEF1 was detected by anti-HEF1 (middle panel) and the levels of R4TD detected by Western blot with anti-TGF-β RI antibody 
(bottom panel).BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/20
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Both APC10 and CDH1 can alter the steady state protein levels of HEF1 Figure 6
Both APC10 and CDH1 can alter the steady state protein levels of HEF1 (A) Overexpressed APC10 caused the 
reduction of the steady-state protein levels of HEF1 and such an activity is compromised in a deletion mutant of APC10 
(APC10 D8) that is defective in binding to Smad3. HEF1 was co-transfected with ubiquitin, Flag-Smad3, T7-APC10 or T7-
APC10 deletion mutant APC10 D8. The expression level of HEF1 was detected by Western blot using anti-p130Cas antibody, 
as shown in the top panel; the expression of Smad3, APC10 and APC10D8 were detected by Western blot using anti-Flag and 
anti-T7, as shown in the bottom panel. (B) CDH1 enhances Smad3-regulated HEF1 degradation. HEF1 was co-expressed in dif-
ferent combinations with myc-CDH1, T7-APC10, Flag-Smad3 and R4T204D (R4TD), a constitutively active type I receptor in 
293 cells. The steady state levels of HEF1 were detected by anti-HEF1 antibody (top panel) and the expression levels of Smad3 
and APC10 were detected with anti-Flag and anti-T7 antibodies, respectively (second and third panels), while the expression 
levels of myc-CDH1 were detected by anti-Myc (fourth panel). To detect R4-TD, cell lysates were blotted with anti-TGF-β RI 
antibody (bottom panel).BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/20
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5 & 6, 7 & 8, 9 & 10). When CDH1 was co-expressed with
Smad3, or with Smad3 and APC10, the p105 HEF1 form
appeared to be less reduced (Fig. 6B, compare lane 5 with
lanes 7, 8 & 9). These data pointed out that Smad3,
APC10 and CDH1 are all capable of altering the protein
levels of HEF1 when they are coexpressed with HEF1.
Discussion
HEF1 has been implicated in many different signaling
pathways such as those mediated by integrin, TCR and
BCR where it plays the role of an adaptor protein. Recent
studies have shown that HEF1 degradation is regulated by
Smad3 via the proteasomal degradation pathway and is
further enhanced by TGF-β stimulation [17]. These find-
ings reveal a novel ability for Smad3, which has been pri-
marily considered as a DNA-binding transcriptional
factor, and also suggest a novel cross-talk mechanism
between TGF-β/activin pathways and multiple HEF1-
involved pathways. The molecular mechanisms underly-
ing Smad3-regulated proteasomal degradation are not
clear. Our current studies revealed the ability of Smad3 to
bind to APC10, which is a regulatory component of the
APC ligase core complex required for substrate interac-
tion, as well as the ability of HEF1 to bind to CDH1,
which is a co-activator of APC ligase for specific substrate
recognition. The interaction between Smad3 and APC10
is subjected to the regulation by the TGF-β type I receptor,
while the interaction between CDH1 and HEF1 is consti-
tutive. Both APC10 and CDH1 exhibit the ability to regu-
late the steady state levels of HEF1 upon co-expression
with HEF1. These data suggests a novel mechanism for
Smad3 to regulate the proteasomal degradation of HEF1
via assisting the recognition of HEF1 by the APC E3 ligase.
The interaction between APC10 and Smad3 was first
observed in the yeast two-hybrid system. This interaction
was confirmed in mammalian over-expression system by
co-immunoprecipitation, then by in vitro GST pull-down
assay, and finally via in vitro binding assays to demon-
strate a potential direct interaction between Smad3 and
APC10. Domain mapping studies showed that Smad3
MH2 domain is necessary and sufficient to bind APC10,
whose C-terminal domain is required for Smad3 binding,
while the N-terminal domain for APC10 stability. These
data strongly suggested a direct and domain-specific inter-
action between Smad3 and APC10. Previously Smad3 has
been shown to recruit APC complex to ubiquitinate its
nuclear interactor SnoN, but it was not clear how Smad3
recruits APC complex [18,19]. The ability of Smad3 to
bind directly to APC10 suggests that this interaction could
be the missing link for Smad3 to recruit APC complex in
the ubiquitination of SnoN. Future studies will be carried
out to directly test this possibility.
Our previous studies have shown that Smad3 interlocks
with HEF1, with the MH1 domain binds to the N-termi-
nal domain of HEF1, while the MH2 domain of Smad3
binds to the C-terminal domain of HEF1 [17]. Consider-
ing the involvement of the MH2 domain of Smad3 in
binding to APC10, we compared the ability of various
deletion constructs of Smad3 MH2 domain in their ability
to bind to APC10 and HEF1. These studies showed that
residues located within 237 to 362 on Smad3 are involved
in Smad3 binding to APC10, while a more localized
region between residues 301 to 330 is involved in binding
to HEF1. These data suggests that Smad3, APC10 and
HEF1 can potentially co-exit in one single complex.
Since APC10 is known to play a role in regulating sub-
strate recognition and ubiquitination by mammalian
APC {Hartmut C. et al., Current Biology 13:1459, 2003}
the interaction between Smad3, APC10 and HEF1 sug-
gests that HEF1 and Smad3 are potential ubiquitination
substrates for APC ligase. Our finding of the direct interac-
tion between HEF1 and the WD40 repeat protein CDH1
further qualifies HEF1 as a substrate for APC, since
interaction with CDH1 or CDC20 has been shown to be a
prerequisite for APC substrates [37]. The role of APC10
and CDH1 in regulating HEF1 degradation was confirmed
by the ability of overexpressed APC10 and CDH1 in
enhancing Smad3-regulated HEF1 degradation in 293
cells (Figure 6). The physical interaction between HEF1
and CDH1, a regulator at late anaphase of cell cycle, could
be functionally linked to a previous observation of the
ability of a processed form of HEF1, p55HEF1, in interac-
tion with mitotic spindles [22]. The exact role of HEF1 in
cell cycle regulation and how Smad3, via interacting with
the co-activators of APC complex to regulate such a role is
also an important subject for future studies.
While Smad3 can regulate the proteasomal degradation of
both HEF1 and SnoN, phosphorylation of Smad3 by the
activated type I receptor is required only for SnoN degra-
dation but not for HEF1 degradation [17-19]. The mecha-
nism for such a difference warrants future investigation.
One apparent difference between HEF1 and SnoN is their
intracellular localization. While HEF1 is predominantly
cytoplasmic, SnoN is primarily a nuclear protein. It has
been shown that the inactive Smad3 is primarily cytoplas-
mic, and its nuclear translocation is triggered upon its
phosphorylation by the type I receptor of TGF-β at the C-
terminal SSVS motif. Thus, the dependence of SnoN deg-
radation on Smad3 phosphorylation at the SSVS motif
could be at least partially due to the dependence of Smad3
phosphorylation for Smad3 accumulation into the
nucleus. However, a recent study (Feng L. et al., manu-
script submitted) indicated that the in vitro translated
Smad3 can induce HEF1 degradation in an in vitro degra-
dation assay, which does not involve the issue of nuclearBMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/20
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localization, thus suggesting that additional component
(s) involving phosphorylation-dependent structural
changes of Smad3 may be involved in regulating SnoN
ubiquitination and degradation. One such structural
change has been recently revealed. Previously it was
shown that inactive unphosphorylated Smad3 is bound
to proteins such as SARA (Smad anchor for receptor acti-
vation) in the cytoplasm and that phosphorylation of
Smad3 by the type I receptor decreases its affinity for
SARA thus allowing Smad3 to interact with the Co-Smad
Smad4 before entering the nucleus [38]. In a recent study,
molecular details were revealed regarding the interaction
between inactive Smad3, SARA and the TGF-β type I
receptor. The inactive Smad3 exists in a monomer form in
a complex with SARA and the TGF-β type I receptor, at the
cell membrane or at early endosome [39,40]. The phos-
phorylation of Smad3 releases it from SARA and allows
Smad3 to adopt a different conformation that favors trim-
mer formation. Interestingly, the later conformation is
preferred by the nuclear oncoprotein Ski [41]. Thus, SARA
serves as a molecular guardian of Smad3 to prevent it
from forming aberrant trimmers for constitutive
activation. Therefore, one possible explanation for the
dependence of Smad3 phosphorylation for SnoN degra-
dation, is that SnoN, like Ski, only interacts with Smad3
in oligomers, which could be either Smad3 homo-trim-
mers or Smad3 (2)/Smad4 (1) hetero-trimmers, and that
the ubiquitination of SnoN occurs in such a complex. For
HEF1, since neither the interaction nor the degradation is
dependent upon Smad3 phosphorylation, we therefore
consider it likely that Smad3 binds to HEF1 in monomeric
form before its phosphorylation and that such a complex
is sufficient for assisting HEF1 ubiquitination and degra-
dation. It also remains a possibility that HEF1 could func-
tion like SARA to keep Smad3 in an inactive
conformation, thereby assisting Smad3 recognition by the
type I receptor kinase and directly regulating Smad3 trim-
mer formation. Our preliminary data have suggested such
an inhibitory role of HEF1 [17]. Future studies of the crys-
tal structures of the complex of Smad3 and HEF1 in the
presence or absence of TGF-β type I receptor cytoplasmic
domain, as well as the structural studies of the complex of
Smad3, HEF1 APC10 and CDH1, as demonstrated here,
will significantly advance our current understandings of
the mechanism and regulation of HEF1 degradation in
TGF-β pathway.
The physiological regulation of the complex formation
between Smad3, APC10, HEF1 and CDH1 is likely very
dynamic and complex. Since all these observations are
made via in vitro systems, we do not know the detailed reg-
ulation of these interactions in specific cell types under
different conditions. The physiological complex forma-
tion between Smad3, HEF1 and APC10 is likely subjected
to constant changes, depending upon the expression
levels of these proteins. It is also possible that the forma-
tion of the complex involves sequential steps. For exam-
ple, Smad3 could first binds to the APC10 before binding
to HEF1 or vise versa and such binding could stabilizes
Smad3 in a favorable conformation for subsequent inter-
action with other proteins, such as CDH1. The regulation
of the formation of this complex could also via phospho-
rylation of HEF1 and Smad3 and via competition involv-
ing other interacting proteins of Smad3 and HEF1. Here
we gain a glimpse of the complexity of the regulation of
HEF1 ubiquitination and degradation in vivo. In 293 cells,
we observed an enhancement effect of TGF-β receptor
activation on Smad3 interaction with APC10, but not on
HEF1 interaction with CDH1 (Fig. 5).
In Figure 7, a cartoon is presented to summarize our data
and present a model for the role of Smad3 interaction
with APC10 in recruiting APC complex for ubiquitination
and degradation of HEF1, downstream of TGF-β type I
receptor activation. In this model, we propose three pos-
sible ways for HEF1 to be ubiquitinated by APC ligase via
the formation of the multimeric complex of Smad3,
HEF1, APC10, CDH1, the latter two of which bring in the
entire APC ligase. The first scenario is that the phosphor-
ylated Smad3, released from SARA, forms a complex with
APC10, while CDH1 interacts with HEF1 constitutively.
The two complexes come together via Smad3 interaction
with HEF1. APC10 assists CDH1 to bring Smad3-bound
HEF1 to APC ligase for the subsequent ubiquitination.
The second scenario is that HEF1 tethers Smad3 in a cyto-
plasmic complex and the type I receptor activation leads
to phosphorylation of Smad3 and the subsequent confor-
mational changes that can enhance its interaction with
APC10, which recruits the APC ligase and assists CDH1 to
bind the substrate HEF1. The third scenario is that mono-
meric unphosphorylated Smad3 and HEF1 forms a consti-
tutive complex to further recruit APC10 and CDH1. Such
a complex may mediate some basal level of constitutive
ubiquitination of HEF1. We recognize that the current
observations need to be followed up in more physiologi-
cal relevant conditions, such that the physiological func-
tions of the observed interactions between these proteins
can be validated.
Conclusions
The studies presented here revealed a physical link
between a key signal transducer of TGF-β (Smad3) and a
component (APC10) of the cell cycle regulatory E3 ligase
APC, and further suggest a molecular mechanism via
which such a physical interaction contributes to the regu-
lation of the protein stability of a multi-domain cytoplas-
mic docking protein HEF1, which is involved in a large
network of signaling events. Since Smad3 interacts with
many other nuclear and cytoplasmic proteins, this obser-
vation may have broad implications for the regulation ofBMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/20
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A cartoon for possible signaling pathways that involve Smad3 interaction with APC10 Figure 7
A cartoon for possible signaling pathways that involve Smad3 interaction with APC10. A cartoon that illustrates 
possible pathways for Smad3-induced HEF1 degradation involving APC10 and CDH1. Please see text for details.BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/20
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these other Smad3 interactors in a similar fashion. While
previous studies of the APC complex have been primarily
limited to cell cycle control, the observations reported
recently extended the role of APC into non-cell cycle
events associated with SnoN [18,19]. Our studies here
provide the detailed link between Smad3 and APC and
now add a cytoplasmic signaling adapter onto the list of
APC substrates. The data imply that the cellular functions
previously viewed as separate are intimately interwoven in
a complex fashion: a cell cycle regulatory E3 ligase is phys-
ically and functionally connected to the vast signaling net-
works involving Smad3 and HEF1. Furthermore the
biological consequences of the TGF-β-induced HEF1 deg-
radation in lymphocytes where HEF1 is predominantly
expressed have yet to be studied and their understanding
could lead to new insights in the molecular events
involved in the onset of complex diseases such as cancers.
Methods
Mammalian cell line
293 cells (human kidney cells transformed with adenovi-
rus 5 DNA) were maintained in Dulbecco's modified
Eagle medium (DMEM, GIBCO/BRL) supplemented with
10% heat inactivated fetal bovine serum (FBS), 25,000
units of penicillin, 25 mg of streptomycin and 5 mL of
200 mM L-Glutamine at 37°C in the presence of 5% CO2.
Antibodies and reagents
Anti-myc (9E10), anti-Smad1/2/3 (H-2), anti-HEF1 (N-
17) and anti-TGF-β RI (V-22) were purchased from Santa
Cruz biotechnology. Anti-p130Cas monoclonal antibody
was purchased from Transduction Laboratories. Anti-T7
(69522–4) was purchased from Novagen. Anti-Flag was
obtained from Sigma and anti-HA was purchased from
Roche. Phosphatase inhibitor (P5726) and protease
inhibitor cocktail (P8340) were purchased from Sigma.
MG132 was dissolved in DMSO and added directly into
cell culture medium to a final concentration of 50 µM for
6 hours before harvest.
Constructs
The pCMV-HEF1 expression vector has been described
previously [22]. All the other mammalian expression con-
structs for HEF1 and Smad3 deletions as well as T7-Ub
were constructed in our lab previously [17]. The mutant
type I receptor R4TD was described previously. Smad3,
APC10 and HEF1 were subcloned into EcoRI/XhoI sites in
pGEX-5X-1 (Amersham) using standard procedures [42].
Smad3 and APC10 were subcloned into EcoRI/XhoI sites
in pCS2+ vector containing a SP6 promoter.
Transfection
293 cells were transfected using the standard CaPO4 pro-
cedure [42] and cells were harvested 24 h after transfec-
tion into ice-cold phosphate-buffered saline (PBS).
Immunoprecipitation and Western blotting
Cells were incubated 30 min on ice in HBS-Lysis buffer
(50 mM HEPES, 5 mM EDTA, 50 mM NaCl, 1% TritonX-
100 supplemented with protease and phosphatase inhib-
itors just prior to use). Cell debris was pelleted by spin-
ning in a microcentrifuge at 14,000 g at 4°C for 10 min
and supernatant was saved for immunoprecipitation and
western blot analysis. For immunoprecipitation, cell
lysates were incubated with 2 µg of primary antibody for
2 h at 4°C followed by an additional 2 h-incubation with
40 µL of 50% slurry of protein G-sepharose 4 Fast Flow
(Amersham). Beads were then washed once using lysis
buffer and 3 times with modified lysis buffer (lysis buffer
containing 0.1% of TritonX-100). The precipitated pro-
teins were eluted in 2× SDS loading buffer (100 mM Tris-
HCl pH 6.8, 4% SDS, 0.2% bromophenol blue and 20%
glycerol) + 10% β-mercaptoethanol, loaded on SDS-PAGE
and transferred onto PVDF membrane (Millipore). Mem-
branes were analyzed by Western blotting [42]. Antibod-
ies were diluted as followed: α-HEF1 (1:500), α-p130Cas
(1:1000),  α-cdc27 (1:500), α-cdc16 (1:500), α-Flag
(1:4000),  α-T7 (1:10000), α-myc (1:1000), α-HA
(1:1000) and α-TGF-β RI (1:4000).
GST pull-down assay
GST-APC10, GST-Smad3 and GST-HEF1 were expressed
and purified from Escherichia coli strain BL-21. Briefly, the
culture was induced at O.D. ~0.6 with 0.4 mM IPTG for 2
to 3 hours. Cells were collected by spinning at 5,000 rpm
at 4°C for ~15 min. The pellet was then resuspended in
Prep buffer (100 mM NaCl, 100 mM Tris-HCl pH8.0, 50
mM EDTA, 2% TritonX-100) supplemented with 2 mM
DTT and 1 mM PMSF. Lysis occurred using10 mg/mL lys-
ozyme (Fisher BP 535-1) in Prep buffer for 30 min on ice
and debris was pelleted by spinning 30 min at 14,000 g at
4°C. Cell lysates were then incubated with a 50% slurry of
Glutathione Sepharose 4 Fast Flow (Amersham) for 40
min at 4°C and washed 3 times with ice-cold PBS. About
4 µg of GST fusion proteins that were immobilized on
beads were incubated with extract in lysis buffer, washed
three times with modified lysis buffer and resuspended in
SDS loading buffer. To test a direct protein-protein inter-
action, proteins were translated in vitro and 35S-labeled by
using the TNT reticulocyte lysates system (Promega). 7 µL
of the in vitro translated product and GST beads were
incubated in 200 µL of modified lysis buffer complete
with protease inhibitors and washed as previously
described. The GST beads were resolved by SDS-PAGE fol-
lowed by Western blot or dried and subjected to
autoradiography.
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- BCR: B-cell receptor
- HEF1: Human Enhancer of Filamentation I
- APC: Anaphase-Promoting Complex
- CDC20: Cell division cycle 20
- CDH1: Cdc20 homolog 1
- MG132: Nα-Benzyloxycarbonyl-L-leucyl-L-leucyl-L-
leucinal [Z-Leu-Leu-Leu-H]
- SDS-PAGE: Sodium Dodecyl Sulfate Polyacrylamide Gel
Electrophoresis
- Mv1Lu cell: Mink Lung cell
- MH1, MH2 domain: Mad homology-1, -2 domain
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